Overview

Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in patients with hypercholesterolemia and hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Collaborator:
Medpace, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid